Back

Renal denervation in hypertensive patients with renal impairment: ultra-long-term follow-up study

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Renal denervation Device Treatment and Intervention ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Li Wang

Tianjin First Central Hospital, Tianjin (China)

7 More presentations in this session

Presentation thumbnail
Effect of catheter-based renal denervation on orthostatic blood pressure adaptations in patients with uncontrolled hypertension
Doctor Z. Zhang (Chengdu, CN)
Abstract Slides Video
Presentation thumbnail
Cost-effectiveness of RF RDN in ESC Hypertension guideline-recommended indications in six European countries: an analysis based on Global SYMPLICITY Registry DEFINE data
Professor R. Schmieder (Erlangen, DE)
Abstract Slides Video
Presentation thumbnail
Therapeutic effects of renal denervation beyond arterial hypertension, a systematic review and meta-analysis.
Mr A. Makris (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Early and sustained blood pressure control from discharge to 12 months after renal denervation: a time in therapeutic range analysis from a nationwide resistant hypertension registry
Doctor L. Wu (Hsinchu, TW)
Abstract Slides Video
Presentation thumbnail
Long-term outcomes after renal denervation in the two defined ESC guideline-recommended patient groups: an analysis from the Global SYMPLICITY Registry DEFINE
Professor F. Mahfoud (Basel, CH)
Abstract Slides

Access the full session

Session thumbnail
Renal denervation

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Early and sustained blood pressure control from discharge to 12 months after renal denervation: a time in therapeutic range analysis from a nationwide resistant hypertension registry
thumbnail
Congress Presentation
Renal denervation for cardiovascular risk reduction
thumbnail
Congress Presentation
The evidence that matters: the SPYRAL HTN clinical journey

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources